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Abstract
Background: A high dietary intake of n-6 compared to n-3 fatty acids (FAs) may promote the
production of pro-inflammatory eicosanoids and cytokines. In two recent studies, short-term (10-
day) duodenal administration of n-3 polyunsaturated fatty acid rich seal oil ameliorated joint pain
in patients with inflammatory bowel disease (IBD). Using unpublished data from these two studies
we here investigated whether normalisation of the n-6 to n-3 FA ratio in blood and tissues by seal
oil administration was associated with improved health related quality of life (HRQOL) as assessed
by the generic short-form 36 (SF-36) questionnaire.
Results: In the first pilot study, baseline n-6 to n-3 FA ratio in rectal mucosal biopsies from 10
patients with IBD (9 of those had joint pain) was significantly increased compared with that in 10
control patients without IBD or joint pain. Following seal oil administration, the n-6 to n-3 FA ratio
of the IBD-patients was significantly lowered to the level seen in untreated controls. In the
subsequent, randomized controlled study (n = 19), seal oil administration reduced the n-6 to n-3
FA ratio in blood similarly and also the SF-36 assessed bodily pain, while n-6 FA rich soy oil
administration had no such effect.
Conclusion: In these two separate studies, short-term duodenal administration of seal oil
normalised the n-6 to n-3 FA ratio in rectal mucosa and improved the bodily pain dimension of
HRQOL of patients with IBD-related joint pain. The possibility of a causal relationship between n-
6 to n-3 FA ratio in rectal mucosa and bodily pain in IBD-patients warrants further investigations.
Background
Most of our dietary fat is derived from vegetable oils, par-
ticularly soy oil, which is rich in the n-6 fatty acid (FA)
linoleic acid (18:2n-6, LA). LA is the precursor of arachi-
donic acid (20:4n-6, AA). Especially linseed oil, and to a
less extent rapeseed oil and soy oil contain substantial
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However, in humans the in vivo conversion of ALA to the
n-3 polyunsaturated fatty acids (PUFAs) eicosapentaenoic
acid (20:5n-3, EPA), and particularly docosahexaenoic
acid (22:6n-3, DHA), is limited [1]. Thus, fatty fish and n-
3 PUFA supplements are important sources of the 'marine'
n-3 PUFAs EPA and DHA [2]. These long chain n-3 PUFAs
decrease the production of pro-inflammatory eicosanoids
and cytokines, directly by replacing AA in blood and tis-
sues and inhibiting AA metabolism or indirectly by alter-
ing gene transcription [3]. The current Western diet with
excessive n-6 FAs compared with n-3 FAs yields a high
ratio of n-6 to n-3 FAs, especially AA to EPA, e.g. in the cell
membrane phospholipids. This may promote chronic
inflammatory diseases like inflammatory bowel disease
(IBD) and rheumatic disorders [4-6].
IBD includes Crohn's disease (CD) and ulcerative colitis
(UC), both chronic inflammatory diseases of the gastroin-
testinal tract, causing abdominal pain and bloody diar-
rhoea. Musculoskeletal (rheumatic) complications,
including joint pain with or without objective signs of
arthritis, are common extraintestinal manifestations [7-
9], contributing to the generally poor health related qual-
ity of life (HRQOL) of IBD-patients [10]. Also, non-steroi-
dal anti-inflammatory drugs (NSAIDs) are poorly
tolerated by these patients. IBD-patients with joint pain
therefore often call for a safe and effective alternative treat-
ment. In a short-term (10-day) pilot study we found a
beneficial effect on IBD-related joint pain of duodenally
administrated n-3 PUFA rich seal oil (10 ml three times
daily) [11]. The promising results were supported in a
recent randomized controlled study comparing the effects
of seal oil and soy oil on IBD-related joint pain [12]. The
joint pain ameliorating effect of seal oil persisted for sev-
eral months after the 10-day treatment period, while soy
oil had no such effect.
Using unpublished data from these two studies [11,12]
we here investigated whether normalisation of the n-6 to
n-3 FA ratio in blood and tissues by seal oil administra-
tion was associated with improved HRQOL as assessed by
the generic short-form 36 (SF-36) questionnaire.
Methods
Patients and controls
In the pilot study, 10 patients with IBD (9 of those had
joint pain) went through a gut lavage fluid procedure
before and after seal oil treatment [11]. Immediately after
emptying their bowels, sigmoidoscopy was performed
with a videoendoscope. Mucosal biopsies were taken
from the rectum, 20–30 cm above the anus, collected on
ice and stored at -80°Celsius. The control patients con-
sisted of 10 males (range 50–67 years, mean 67 years)
with prostate cancer, but without IBD or joint pain, rou-
tinely assessed before radiation therapy. Mucosal biopsies
were taken without prior emptying of the bowels, by rec-
toscopy from the posterior rectal wall, 10 cm from the
anal verge, collected on ice and stored at -80°Celsius.
Fatty acid composition in biopsies was analysed by gas
liquid chromatography as previously described [11]. In
the controlled study, seventeen of the nineteen patients
with IBD-related joint pain [12] filled in a translated and
validated Norwegian version of the Medical Outcome
Study (MOS) SF-36 health survey questionnaire [13-15]
before and after seal oil (n = 9) or soy oil (n = 8) adminis-
tration, in addition to 1, 2, 4 and 6 months post-treat-
ment. SF-36 is a generic self-administrated HRQOL
questionnaire consisting of 36 questions, assessing eight
health concepts (physical functioning, role limitations
due to physical problems, social functioning, bodily pain,
general mental health, role limitations due to emotional
problems, vitality and general health perceptions). Final
values from the SF-36 questionnaire ranged from 0 (very
poor) to 100 (very well). The regional committee for med-
ical research ethics approved these studies and all patients
gave written informed consent before inclusion.
Statistics
Data were analysed and displayed using the GraphPad
Prism 4 (GraphPad Software Inc, San Diego, USA) statis-
tical software package or SPSS Release 9.0.0 software
(SPSS Inc, Chicago, IL, USA). All values were expressed as
mean ± standard error of the mean (SEM). Effect of treat-
ment was calculated as change (in absolute values) from
baseline. Area under the curve (AUC, area between the
curve and baseline, zero) for the entire period from start
of treatment until 6 months post-treatment was calculated
using the trapezoid method. Group differences were com-
pared by unpaired Student's t test (two-sided). Differences
from baseline to end of treatment were evaluated by
paired t-test. P values < 0.05 were regarded as statistically
significant.
Results
Biopsy fatty acid composition
Compared with controls, higher ratios of n-6 to n-3 FAs (P
= 0.001) and AA to EPA (8.5 ± 1.1 vs 2.9 ± 0.7, P = 0.0004)
were found in baseline rectal mucosa from the patients
with IBD-related joint pain (Table 1, Figure 1). These dif-
ferences vanished after seal oil treatment (Table 1, Figure
1). Also a higher Σ n-6 FAs (P = 0.04), LA (P = 0.02) and
18:1n-9 (P = 0.004) and lower Σ n-3 FAs (P = 0.0004),
EPA (P = 0.0003), DHA (P = 0.0006), Σ saturated (P =
0.01) and 17:0 (P = 0.02) were found in rectal mucosa
from the patients with IBD-related joint pain before treat-
ment with seal oil (Table 1). These differences also van-
ished after seal oil treatment (Table1). Seal oil treatment
reduced Σ monoenes in rectal mucosa from the IBD-Page 2 of 6
(page number not for citation purposes)
Lipids in Health and Disease 2006, 5:6 http://www.lipidworld.com/content/5/1/6patients to a significantly lower level (P = 0.003) than that
seen in untreated controls.
Health related quality of life
Compared with soy oil, seal oil administration signifi-
cantly reduced the SF-36 assessed bodily pain (Table 2).
SF-36 also revealed significant within group improve-
ments in bodily pain (P = 0.004), mental health (P = 0.03)
and physical component score (P = 0.002), and a signifi-
cant aggravation in emotional role functioning (P = 0.02)
after seal oil treatment (Table 2). No significant group dif-
ferences in AUC for the period from before treatment
until 6 months post-treatment were found. However sig-
nificant with-in group improvements were found in AUC
for the period from before treatment until 6 months post-
treatment; in the seal oil group for bodily pain (P = 0.04),
mental health (P = 0.0009) and mental component score
(P = 0.02) and in the soy oil group for mental health (P =
0.049). Generally both groups improved in the physical
dimensions of SF-36 after oil administration, with more
profound effects in the seal oil group. Also, there were no
changes in the psychometric dimensions of SF-36, except
for an aggravation in role limitations due to emotional
problems during and soon after oil treatments, but not
during follow-up (data not shown).
Discussion
Fatty acid composition
During the last 50 to 100 years the typical Western diet has
contained increasing amounts of n-6 FAs and decreasing
amounts of n-3 FAs [6]. Vegetable oils containing much n-
6 FAs, especially soy oil, are widely used in foodstuffs and
Biopsy AA to EPA ratio in IBD-patients before and after seal o l compared with controlsF gure 1
Biopsy AA to EPA ratio in IBD-patients before and 
after seal oil compared with controls. Normalisation of 
individual ratios of arachidonic acid (20:4n-6, AA) to eicosap-
entaenoic acid (20:5n-3, EPA) in rectal mucosal biopsies from 
nine of the ten IBD-patients (data from the pilot study [11]) 
after seal oil (SO) treatment compared with rectal mucosal 
biopsies from ten controls.
Table 1: Biopsy fatty acid-profiles from IBD-patients before and after seal oil treatment compared with controls
Fatty acid Controls IBD before IBD after P-value before P-value after
Σ Saturated 36.9 ± 2.1 32 ± 1 31 ± 3 0.01 n.s.
14:0 2.9 ± 0.6 1.4 ± 0.3 1.2 ± 0.3 0.02 0.01
16:0 20.2 ± 0.4 17.9 ± 0.9 17 ± 1 0.008 0.02
17:0 0.90 ± 0.01 0.61 ± 0.08 0.7 ± 0.1 0.02 n.s.
18:0 11.1 ± 0.7 11 ± 1 12 ± 1 n.s. n.s.
Σ Monoenes 31 ± 4 31 ± 2 24 ± 2 n.s. 0.003
16:1 n-7 1.9 ± 0.2 2.0 ± 0.5 1.5 ± 0.3 n.s. n.s.
16:1 n-9 0.50 ± 0.01 0.40 ± 0.04 0.37 ± 0.05 n.s. n.s.
18:1 n-7 2.3 ± 0.1 2.4 ± 0.2 2.0 ± 0.2 n.s. n.s.
18:1 n-9 19 ± 1 25 ± 1 19 ± 1 0.004 n.s.
20:1 n-9 2.9 ± 0.6 0.13 ± 0.07 0.4 ± 0.3 0.0008 0.003
Σ n-6 17 ± 2 24 ± 2 19 ± 1 0.04 n.s.
18:2 n-6 11 ± 2 16 ± 1 12.1 ± 0.6 0.02 n.s.
20:3 n-6 tr. 1.5 ± 0.2 1.0 ± 0.1 < 0.0001 0.0004
20:4 n-6 5.7 ± 0.9 6 ± 1 6 ± 1 n.s. n.s.
Σ n-3 9 ± 1 4.1 ± 0.5 9 ± 1 0.0004 n.s.
18:3 n-3 0.5 ± 0.1 0.4 ± 0.1 0.24 ± 0.08 n.s. n.s.
20:5 n-3 2.6 ± 0.3 0.81 ± 0.05 3.4 ± 0.4 0.0003 n.s.
22:5 n-3 0.7 ± 0.1 0.6 ± 0.2 0.9 ± 0.2 n.s. n.s.
22:6 n-3 4.6 ± 0.4 2.2 ± 0.3 4.3 ± 0.6 0.0006 n.s.
n-6/n-3 2.2 ± 0.4 6.6 ± 1.1 2.2 ± 0.2 0.001 n.s.
Data from the pilot study [11], IBD-group (n = 10) and control group (n = 10). Data presented as percentage of fatty acids, mean ± SEM. Identified 
fatty acids ranged from 94–98 %. tr. = trace. n.s. = not significant (p > 0.05). P-value before = controls versus IBD-patients before seal oil treatment. 
P-value after = controls versus IBD-patients after seal oil treatment.Page 3 of 6
(page number not for citation purposes)
Lipids in Health and Disease 2006, 5:6 http://www.lipidworld.com/content/5/1/6as spreads, mainly due to its low cost. In an evolutionary
aspect our ancestors evolved on a diet with a n-6 to n-3 FA
ratio close to 1:1, while today this ratio is probably 5–15:1
[6].
The importance of the n-6 to n-3 FA ratio for development
of disease was demonstrated in a recent transgenic mouse
model [16]. In this study an approximately 1:1 ratio of n-
6 to n-3 FAs was achieved in different cells and tissues of
fat-1 mice compared with a ratio of 20–50: 1 in wild type
mice. This protected against cancer growth, cardiac
arrhythmia and had most probably collateral health ben-
efits in fat-1 mice compared with wild type mice. Simi-
larly, a seal oil-induced lowering of n-6 to n-3 FA ratio,
especially AA to EPA, may have health benefits in
humans. E.g. by reducing the production of highly pro-
inflammatory eicosanoids and cytokines both locally in
the intestine and systemically, and possibly thereby also
influence joint pain. However, whether amelioration of
bodily pain was causally related to the normalisation of
the n-6 to n-3 FA ratio in rectal mucosa is not known.
A possible limitation of our biopsy FA comparison was
the use of elderly men with prostate cancer as a control
group. Elderly people normally eat more n-3 PUFA rich
fish than younger people and may have a lower blood and
tissue ratio of n-6 to n-3 FAs in general, however we did
not assess the diet in this study.
Health related quality of life
For assessing subjective aspects of a patients' health, i.e.
HRQOL, it is important to use a generic HRQOL ques-
tionnaire, e.g. the widely used SF-36, together with a dis-
ease specific questionnaire as used in our former studies
[10-12]. HRQOL is particularly important when objective
clinical findings are scarce as often is the case in IBD-
related joint pain. In a recent population based cohort
study, sixteen percent of 521 IBD-patients had non-
inflammatory joint pain with a considerable negative
impact on HRQOL [17]. The even more pronounced
reduction of HRQOL in our patients might be due to the
fact that 10 of our 19 IBD-patients had objective arthritis
[12].
The aggravation in role limitations due to emotional
problems after both oil treatments may be attributed to
anxiety using the nasoduodenal feeding tube, which in
some patients resulted in emotional problems and work-
related inconvenience.
A limitation with using SF-36 questionnaire in our study
was that the SF-36 is designed to assess health status over
the last 4 weeks. We used the SF-36 questionnaire just
before and after oil administration (10 days) and then at
1, 2, 4 and 6 months post-treatment. Thus we may have
lost a further positive (for physical dimensions) or nega-
tive (especially for role limitations due to emotional prob-
lems) treatment effect when we applied the SF-36 with
only a 10-day interval.
Seal oil versus fish oil
Traditionally, cod liver oil or other fish oils have been
used in clinical studies of n-3 PUFAs. However, the initial
studies of n-3 PUFAs were performed in Greenland Eski-
mos known to eat substantial amounts of sea mammals,
i.e. seal and whale meat and blubber [18,19]. Greenland
Eskimos had a low prevalence of common westernized
diseases like myocardial infarction, diabetes mellitus,
bronchial asthma, multiple sclerosis and psoriasis [20],
notably before the Western diet became more common in
the larger communities of Greenland.
Seal oil contains slightly less EPA and DHA than fish oil,
but approximately 3 to 4 fold more DPA, giving an equiv-
alent total n-3 fatty acid level [21]. The n-3 PUFAs in fish
oil are mainly located in sn-2 position of the triacylglyc-
erol (TAG) molecule, while they are located almost exclu-
sively in sn-1 or sn-3 position of TAG from seal oil [22,23].
Table 2: SF-36 scores before and after treatment with seal oil or soy oil in IBD-patients
Before seal oil After seal oil Before soy oil After soy oil P-value
Physical functioning 72.8 ± 6.0 80.0 ± 3.5 68.8 ± 8.3 70.4 ± 9.7 0.36
Role physical 30.6 ± 12.3 34.3 ± 12.5 25.0 ± 14.2 31.3 ± 15.5 0.80
Role emotional 66.7 ± 14.1 41.7 ± 15.1 54.2 ± 17.7 45.8 ± 16.6 0.24
Bodily pain 36.3 ± 6.4 57.7 ± 8.5 35.9 ± 6.3 46.7 ± 10.4 0.01
Social functioning 51.4 ± 3.3 51.4 ± 2.5 54.7 ± 2.3 50.0 ± 2.4 0.36
Mental health 67.1 ± 7.1 73.8 ± 6.2 63.0 ± 8.1 65 ± 6 0.31
Vitality 30.0 ± 3.1 38.3 ± 5.7 41.9 ± 8.2 43.8 ± 9.2 0.35
General health 43.3 ± 6.1 51.2 ± 4.9 40.4 ± 5.4 43.6 ± 5.5 0.50
Physical component score 36.7 ± 2.0 42.8 ± 1.9 34.6 ± 2.9 37.0 ± 3.6 0.15
Mental component score 39.5 ± 2.7 37.0 ± 3.5 38.1 ± 4.1 36.7 ± 3.4 0.63
Data from the controlled study [12], seal oil group (n = 9) and soy oil group (n = 8). No significant group differences at baseline. Boldface numbers 
= significantly group difference after treatment.Page 4 of 6
(page number not for citation purposes)
Lipids in Health and Disease 2006, 5:6 http://www.lipidworld.com/content/5/1/6Chylomicrons resulting from TAG digestion are desig-
nated for lymphatic transport [24]. They reflect the dietary
TAGs with respect to both fatty acid profile and molecular
position of the n-3 PUFAs [23,25]. However, in a recent
review focusing mainly on metabolism of structured
TAGs, the molecular position of n-3 PUFAs on TAG did
not seem to play a critical role [26]. Whether this also
applies for natural TAGs with complex fatty acid compo-
sitions remains to be elucidated, particularly in specific
cells and tissues, not only in total plasma. Anyway, seal oil
is an interesting alternative source of n-3 PUFAs.
Duodenal administration of dietary oils
During gastric emptying only a few ml of gastric content is
passed through to the duodenum per minute. Acute
administration of 10 ml of oil directly into the duodenum
is clearly unphysiological and might yield a higher bolus
of n-3 PUFAs into the circulation as compared to oral
administration [12]. However our unpublished data
showed comparable plasma incorporation of n-3 PUFAs
from seal oil (10 ml × 3 per day) during duodenal versus
oral administration in healthy volunteers (n = 16), and a
tendency to abnormally high faecal fat levels. Thus malab-
sorbed n-3 PUFAs may have passed to the colon where it
can potentially reinforce the mucus as seen with retarded
release phosphatidylcholine in UC [27,28]. Studies of n-3
PUFA administrations in IBD have showed inconsistent
findings [29], possibly due to variations in study design.
One of the studies showing most beneficial effect
(reduced relapses in CD), applied fish oil capsules which
contained free fatty acids, coated in order to resist gastric
acid [30]. I.e. delivery to the distal gut may be important
in order to achieve beneficial effects of n-3 PUFA admin-
istrations.
Recently, high fat enteral nutrition [31,32] was shown to
activate a 'nicotinic anti-inflammatory pathway', medi-
ated by the vagus nerve, being able to inhibit pro-inflam-
matory cytokine production [33,34]. Duodenal
administration of seal oil to the principal site of lipid
digestion yields free long chain n-3 PUFAs known to stim-
ulate cholecystokinin (CCK) release [35]. CCK is an
important neuro-transmitter of the afferent vagus nerve.
Hence, duodenal administration of bolus doses of 10 ml
seal oil three times daily may strongly activate the vago-
vagal, anti-inflammatory reflex and partly explain the
rapid amelioration of bodily pain. By similar mechanisms
trauma and surgery patients may benefit from early
enteral nutrition [32]. However, further studies of the
effects of these forms of fat administrations are needed.
Conclusion
In these two separate studies, short-term duodenal admin-
istration of seal oil normalised the n-6 to n-3 FA ratio in
rectal mucosa and improved the bodily pain dimension of
HRQOL of patients with IBD-related joint pain. The pos-
sibility of a causal relationship between n-6 to n-3 FA ratio
in rectal mucosa and bodily pain in IBD patients warrants
further investigations.
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